Skip to main content Accessibility help

Factors that influence patients' attitudes to antipsychotic medication

  • Farhan Haq (a1), Caragh Behan (a1), Nicola McGlade (a1), Una Mulkerrin (a1), Eadbhard O'Callaghan (a2), Anthony Kinsella (a3), Aiden Corvin (a4), Gary Donohoe (a4) and Michael Gill (a4)...


Objective: The aim of this study was to investigate the attitudes to medication in relation to insight, purpose in life, symptoms and sociodemographic factors among a cohort of stable patients with a diagnosis of schizophrenia and schizoaffective disorder.

Method: We included 70 patients with a diagnosis of schizophrenia and schizoaffective disorder attending a Dublin suburban mental health service. All participants were 18 years or older and were excluded if they had a learning disability, acquired brain injury resulting in unconsciousness, and psychosis secondary to a general medical condition or illicit substance misuse. All participants were given self report questionnaires which included Drug Attitude Inventory (DAI-30), Birchwood Insight Scale, and Purpose in Life test. Symptoms were assessed using the Scale for Assessment of Positive and Negative symptoms. All data was analysed using the Statistical Package for the Social Sciences.

Results: We found that 86% (n = 60) of the participants had positive attitudes to medication, and 82% (n = 58) had good insight into their illness. Only 27% (n = 19) were found to have a definite purpose in life. There was a significant negative relationship between attitudes to medication and delusions (r = -0.25, n = 70, p < 0.05) and a significant positive relationship between insight and attitudes to medication (r = 0.0.28, n = 70, p < 0.05).

Conclusion: Many factors are involved in the multifaceted issue of attitudes to medication. Researchers must realise that these factors do not remain constant and may change with time and over the course of illness and treatment.


Corresponding author

*Correspondence Email:


Hide All
1.DiMatteo, MRet al.Variations in patient's adherence to medical recommendations: a quantitative review of 50 years of research. Med Care 2004; 42: 200–9.
2.Fenton, WS, Blyler, CR, Heinssen, RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings: Schiz Bull 1997; 23: 637651.
3.Pool, VE, Elder, ST. A selected review of the literature and an empirical analysis of drug treatment compliance by schizophrenic patients. Int Rev Appl Psychol 1986; 35: 547576.
4.McEvoy, JP, Howe, AC, Hogarty, GE. Differences in the nature of relapse and subsequent inpatient course between medication, medication-compliant and noncompliant schizophrenic patients. J Nerv Ment Dis 1984; 172: 412416.
5.Leucht, S, Heres, Set al.Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia J Clin Psychiatry 2006; 67(5): 38.
6.Ley, P.The problem of patients' non-compliance. In: Marcer, D, ed. Psychology and Health Series; vol 4. Communicating with Patients: Improving Communication, Satisfaction and Compliance. London, England: Chapman and Hall; 1992: 5371.
7.Hofer, A, Rettenbacher, MA, Edlinger, M, Kemmler, G, Widschwendter, CG, Fleischhacker, WW. Subjective response and attitude toward antipsychotic drug therapy during the initial treatment period: a prospective follow-up study in patients with schizophrenia. Acta Psychiatr Scand 2007; 116(5): 354–61.
8.Cabeza, IG, Amador, MS, Lopez, CA, Gonzalez de Chavez M. Subjective response to antipsychotics in schizophrenic patients: clinical implications and related factors. Schiz Res 2000; 21; 41 (2): 349–55.
9.Lambert, M, Conus, P, Eide, Pet al.Impact present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence. Eur Psychiatry 2004; 19(7): 415422.
10.Kampman, O, Laippala, P, Vaananen, Jet al.Indicators of medication compliance in first-episode psychosis. Psychiatry Res 2004; 110(1): 3948.
11.O' Donnell, C, Donohoe, G, Sharkey, Let al.Compliance therapy: a randomised controlled trial in schizophrenia. BMJ 2003; 327: 834.
12.Hogan, TP, Awad, AG, Eastwood, MR. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 1983; 13: 177183.
13.Trauer, T, Sacks, T. The relationship between insight and medication adherence in severely mentally ill clients treated in the community. Acta Psychiat Scand 2000; 102: 211216.
14.Donohoe, G, Owens, N, O' Donnell, C, Burke, T, Moore, L, Tobin, A, O'Callaghan, E. Predictors of compliance with neuroleptic medication among inpatients with schizophrenia: a discriminant function analysis. Eur Psychiatry 2001; 16: 293–8.
15.Kamali, M, Kelly, L, Gervin, M, Browne, S, Larkin, C, O'Callaghan, E. Psychopharmacology: Insight and Comorbid Substance Misuse and Medication Compliance Among Patients with Schizophrenia. Psychiatr Serv 2001; 52:161166.
16.Crumbaugh, , Maholick, LT. An experimental study in existentialism: the psychometric approach to Frankl's concept of noogenic neurosis. J Clin Psychol 1964; 20: 200207.
17.Zika, S, Chamberlain, K. On the relation between meaning in life and psychological well being. Br J Psychol 1992; 83: 133–45.
18.Thompson, N, Croker, J, Krause, J, Henry, E. Purpose in Life as a mediator of adjustment after spinal cord injury. Rehab Psychol 2003; 48: 100108.
19.Turner, N, Jackson, D, Renwick, Let al.What Influences Purpose in Life in First – Episode Psychosis? Br J Occupational Ther 2007: 70(8): 16.
20.Birchwood, M, Smith, J, Drury, Vet al.A self-report insight scale for psychosis: reliability, validity and sensitivity to change. Acta Psychiatrica Scand 1994; 89: 6267.
21.Crumbaugh, Maholick LT. Manual of instructions for the purpose in life test. Murfreesboro, TN: Psychometric Affiliates, 1981.
22.Day, JC, Bentall, RP, Roberts, Cet al.Attitudes toward Antipsychotic Medication; the Impact of Clinical Variables and Relationships with Health Professionals. Arch Gen Psychiatry 2005; 62: 717724.
23.Marder, SR, Mebane, A, Ckien, CP, Winslade, WJ, Swann, E, Van Putten, T. A comparison of patients who refuse and consent to neuroleptic treatment. Am J Psychiatry 1983; 140: 470472.
24.Barkto, G, Herczeg, I, Zador, G. Clinical symptomatology and drug compliance in schizophrenic patients. Acta Psychiatr Scand 1988; 77: 7476.
25.Garavan, J, Browne, S, Gervin, M, Lane, A, Larkin, C, O'Callaghan, E. Compliance with Neuroleptic Medication in Outpatients with Schizophrenia; Relationship to Subjective Response to Neuroleptics; Attitudes to Medication and Insight. Compr Psychiatry 1998; 39:215219
26.Kroenke, K. Polypharmacy: Causes, consequences, and cure. Am J Med 1985; 79: 149152.
27.Murray, MD. Polypharmacy: Management of therapeutic regimens. In: Mezey, MD, Bottrell, MM, Berkman, BJ (Eds). The Encyclopedia of Elder Care: The Comprehensive Resource on Geriatric and Social Care. New York: Springer Publishing Company; 2000.
28.Kamali, M, Kelly, BD, Clarke, Met al.A prospective evaluation of adherence to medication in first episode schizophrenia: Eur Psychiatry 2006; 21 (1): 2933.
29.DiMatteo, MR. Social support and patient adherence to medical treatment: a metaanalysis. Health Psychol 2004; 23: 207–18.


Factors that influence patients' attitudes to antipsychotic medication

  • Farhan Haq (a1), Caragh Behan (a1), Nicola McGlade (a1), Una Mulkerrin (a1), Eadbhard O'Callaghan (a2), Anthony Kinsella (a3), Aiden Corvin (a4), Gary Donohoe (a4) and Michael Gill (a4)...


Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed